Targeted Professional Buyers Depisteo LLC serves a specialized audience including Occupational Health, Optometrists, DMV, Hospitals, General Practitioners, and Lung Specialists. Potential sales opportunities exist by tailoring outreach to clinics and health facilities that require efficient, portable screening devices and could benefit from bundled offerings of VT1 Vision Screener and Spirolyser Q13 Spirometer with customizable test sequences.

Compact Portfolio Appeal The VT1 Vision Screener and Spirolyser Q13 Spirometer are described as complete, fast, lightweight, and easy to transport. Use this to position Depisteo’s devices to small to mid-sized practices and mobile health units seeking quick deployment, reduced patient disruption, and minimal post-sale maintenance, expanding addressable market beyond large institutions.

No-Containment Advantage The Spirolyser Q13 emphasizes a No Contact No Risk concept with no disinfection required and no cross-contamination. This is a strong differentiator in post-pandemic procurement discussions and can drive pilots in patient-facing settings like clinics and DMV offices where hygiene and turnaround time are critical.

Customization & Automation The ability to customize test sequences and scoring for pass/fail reporting provides a compelling upsell to practices with varying risk profiles. Sales opportunities include offering configurable bundles, training, and ongoing software updates to maintain compliance with evolving screening guidelines.

European backing & credibility Depisteo LLC is the US subsidiary of FIM Medical S.A.S., which can be leveraged to reassure buyers about product quality, regulatory alignment, and long-term support. Leverage the parent company’s scale to pursue enterprise opportunities, extended warranties, and volume discounts for hospitals and larger clinics.